Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations References Novartis pipeline in registration Oncology Code Name Solid tumors LEE011 KisqaliⓇ INC424 JakaviⓇ Immunology Mechanism Indication(s) CDK4/6 Inhibitor JAK1/2 inhibitor HR+/HER2- BC (adj) Acute GVHD, pediatrics Chronic GVHD, pediatrics Code Name IGE025 XolairⓇ Mechanism IgE inhibitor Indication(s) Food Allergy INNOVATION □ NOVARTIS Reimagining Medicine Novartis Q4 Results | January 31, 2024 41

View entire presentation